What I've Learned From Treating Over 1,500 Faces: A Taiwanese Injector's Perspective on Asian Facial Aesthetics
By Stephanie Hwang, NP
Co-Founder, Mosaic Skin Studio
Oakland & San Francisco
Over the years, I've treated more than 1,500 faces, with many patients specifically seeking me out because they want an injector who understands Asian facial features.
And I understand why.
For some patients, there's a sense of comfort in knowing their provider may have firsthand familiarity with their facial features, cultural background, or aesthetic preferences. Others have had experiences where they felt their concerns weren't fully understood.
But here's something I've learned: being Asian doesn't automatically make someone an expert in treating Asian faces.
Expertise comes from clinical training, experience, understanding facial anatomy, and developing a deeper appreciation for how even small treatment decisions can affect the overall balance of the face.
And TBH, this is an ongoing learning process. I'm constantly learning and refining my approach with every patient I treat.
How I Approach Asian Facial Aesthetics Differently
One of the most important things I've learned in aesthetic medicine is that there is no one-size-fits-all approach to treating the face.
The Asian face itself is incredibly diverse. Facial anatomy, bone structure, muscle strength, skin characteristics, and aesthetic preferences vary tremendously, even among people of the same ethnicity.
What works beautifully for one person might not be the best approach for another.
These are also the types of observations I share with our injectors at Mosaic Skin Studio. Whether an injector is Asian or not, I want them to understand how differences in facial anatomy can influence their treatment decisions.
Two examples I often discuss are masseter Botox for facial balancing and choosing the right neurotoxin, whether that's Botox, Xeomin, or another brand.
1. Masseter Botox: Why a Slimmer Face Isn't Always a Better Face
One of the anatomical features I pay particular attention to when evaluating Asian faces is the masseter muscle.
The masseters are the large muscles on either side of the jaw that help us chew. Their size and strength can contribute significantly to the width and shape of the lower face.
In some Asian patients, more prominent masseter muscles contribute to a wider or more square-shaped jawline.
I'd estimate that about half of my masseter patients are of Asian descent. Of those patients, roughly half come to me because of jaw pain, clenching, or stiffness. The other half are primarily interested in an aesthetic outcome: a softer, more V-shaped or tapered face.
For patients who prefer a more tapered appearance, masseter Botox, sometimes called jaw slimming Botox, can be an option. For patients experiencing pain or clenching, it's important to evaluate the underlying cause rather than assume Botox is the right treatment.
But here's the thing: I don't believe that a slimmer face is always a better face.
This is where understanding facial proportions becomes particularly important.
As we age, changes in facial fat, skin elasticity, and soft tissue support can influence how long, narrow, or full our faces appear. Reducing masseter volume may further change those proportions.
For some patients, reducing masseter bulk can create a more balanced lower face.
For others, particularly those who already have a longer or narrower facial structure, reducing the masseters may make their face appear more elongated or contribute to unwanted hollowing.
In certain patients, I actually prefer to preserve some masseter fullness to maintain balance between the upper, middle, and lower thirds of the face.
This is something I emphasize when training other injectors: don't just identify a muscle that can be treated. Understand what that muscle is doing, both functionally and aesthetically, before deciding whether treatment makes sense.
And I won't bore you with all the scientific details, but there is research supporting this individualized approach.
A 2023 review published in Aesthetic Surgery Journal Open Forum examined masseter botulinum toxin treatment in Asian populations, discussing facial anatomy, individualized treatment planning, and potential complications.
It's a good reminder that even a relatively straightforward injectable treatment requires thoughtful clinical judgment.
2. Botox vs. Xeomin: Why Neurotoxin Choice Matters
Another consideration when I'm treating patients is which neurotoxin to use.
Most people are familiar with Botox, but there are several botulinum toxin formulations available, including Xeomin and Dysport, all readily available at Mosaic Skin Studio.
While they all work by temporarily relaxing targeted muscles, patients may describe different experiences with their treatments. I make it a point to discuss these expectations during consultations with new patients.
One of the things I consider when treating Asian patients is their natural facial muscle activity, including their forehead, eyebrows, and the muscles around their eyes.
Facial anatomy, brow position, eyelid structure, and muscle recruitment patterns can vary substantially between individuals.
When selecting a neurotoxin, I consider the patient's anatomy and muscle strength, their desired results, their prior experience with different products, and how much movement they want to preserve.
In my experience, many of my patients really love Xeomin, and it has become one of my preferred neurotoxins.
Why I Often Choose Xeomin
Xeomin (incobotulinumtoxinA) is a botulinum toxin type A product that differs from Botox (onabotulinumtoxinA) in its formulation.
Xeomin contains the active neurotoxin without the accessory complexing proteins present in the Botox formulation.
I want to be clear that this is a clinical preference, not a conclusion that Xeomin is inherently better for Asian patients.
A 2016 study published in the Journal of Drugs in Dermatology evaluated Xeomin in Asian and non-Asian patients receiving treatment for glabellar frown lines. The study found generally similar efficacy and no clinically relevant safety differences between groups, although the number of Asian participants was small.
Current evidence does not establish that ethnicity alone should determine which brand of neurotoxin a patient receives.
For me, product selection is one component of treatment planning. Injection placement, dosage, muscle activity, and an understanding of the patient's goals are equally important.
What I Teach Our Injectors About Neurotoxin Selection
When training our injectors, I encourage them to look beyond the brand name.
I want them to understand why we might select one product over another, why we might adjust our approach to specific muscles, and how those choices can affect the patient's overall expression.
Every face has its own balance of muscle strength, anatomy, and movement.
Passing Down Experience Is How We Become Better Injectors
One thing I've learned through years of treating patients is that clinical experience becomes even more valuable when it's shared.
At Mosaic, I want our injectors to understand not just how to perform a treatment, but how to think critically about each face.
Whether we're discussing masseter anatomy, brow positioning, or choosing between Botox and Xeomin, these decisions should be grounded in careful assessment and an understanding of why we're doing what we're doing.
I believe this is how injectors grow: through repetition, mentorship, clinical observation, and learning from the experience of others.
And this philosophy isn't limited to treating Asian patients. It's how we approach every patient at Mosaic Skin Studio.
Stephanie Hwang is a Nurse Practitioner and Co-Founder of Mosaic Skin Studio, a medical aesthetics practice serving Oakland and San Francisco, California.
Medical disclaimer: This article is for educational purposes and does not constitute individualized medical advice. Cosmetic masseter botulinum toxin treatment is an off-label use in the United States. Botulinum toxin treatment carries risks, and individual treatment recommendations should be made following an appropriate clinical evaluation.
References
Wu Y, Zeng D, Wu S. (2023). Botulinum Toxin Type A for the Treatment of Masseter Muscle Prominence in Asian Populations. Aesthetic Surgery Journal Open Forum.
Seo K, Tsai TF, Chao YY, Goodman GJ. (2016). Efficacy and Safety of IncobotulinumtoxinA in Asian Subjects: A Pooled Analysis of Clinical Trials in the Treatment of Glabellar Frown Lines. Journal of Drugs in Dermatology.
